Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Receivables - Other (2024 - 2025)

Historic Receivables - Other for Avidity Biosciences (RNA) over the last 2 years, with Q3 2025 value amounting to $15.0 million.

  • Avidity Biosciences' Receivables - Other changed N/A to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year change of. This contributed to the annual value of $9.4 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Avidity Biosciences' Receivables - Other stood at $15.0 million.
  • Avidity Biosciences' Receivables - Other's 5-year high stood at $15.0 million during Q3 2025, with a 5-year trough of $8.5 million in Q2 2025.